HEPATITIS B CORE PROTEIN MODULATORS

(19)

(11)

EP 3 349 581 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	05.01.2022 Bulletin 2022/01

(45)	Mention of the grant of the patent:
	01.12.2021 Bulletin 2021/48

(21)	Application number: 16847305.6

(22)	Date of filing: 15.09.2016

(51)

International Patent Classification (IPC):

C07D 401/12^(2006.01)
C07D 417/12^(2006.01)
C07D 243/38^(2006.01)
C07D 471/04^(2006.01)
C07D 281/16^(2006.01)
A61K 31/553^(2006.01)
A61P 31/20^(2006.01)

C07D 413/12^(2006.01)
C07D 417/14^(2006.01)
C07D 453/02^(2006.01)
C07D 267/20^(2006.01)
A61K 31/551^(2006.01)
A61K 31/554^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61P 31/20; C07D 267/20; C07D 453/02; C07D 417/12; C07D 281/16; C07D 401/12; C07D 243/38; A61K 45/06; C07D 471/04; C07D 403/12; C07D 413/12; C07D 417/14

(86)	International application number:
	PCT/US2016/051949

(87)	International publication number:
	WO 2017/048962 (23.03.2017 Gazette 2017/12)

(54)	HEPATITIS B CORE PROTEIN MODULATORS HEPATITIS-B-KERN-PROTEINMODULATOREN MODULATEURS DES PROTÉINES DU NOYAU DE L'HÉPATITE B

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

15.09.2015 US 201562218815 P

(43)	Date of publication of application:
	25.07.2018 Bulletin 2018/30

(73)	Proprietors:
	Assembly Biosciences, Inc. South San Francisco, CA 94080 (US) Indiana University Research and Technology Corporation Bloomington IN 47405 (US)

(72)	Inventors:
	TURNER, William Bloomington, IN 47408 (US) MAAG, Hans 79692 Kleires Wiesental (DE) FRANCIS, Samson Indianapolis, IN 46204 (US)

(74)	Representative: Harris, Jennifer Lucy et al
	Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)

(56)

References cited: :

WO-A1-2013/006394
WO-A1-2015/138895

WO-A1-2015/017412
US-A1- 2007 105 835

DATABASE PUBCHEM [Online] 09 August 2005 XP055371494 Database accession no. 201327
XIAO ET AL.: 'Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists' J MED CHEM. vol. 57, 2014, pages 3450 - 3463, XP055140768

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).